Salarius Pharmaceuticals Inc.
13F holders, Q1 2025 (March 31)9holders +3
3new positions
0sold out
$0.75avg. 13F price*
At the end of Q1 2025, 9 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings, up 3 from Q4 2024. 3 opened new positions and 0 sold out. The largest holders were UBS Group AG ($25K), Two Sigma Securities, LLC ($12K) and Geode Capital Management, LLC ($9K).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X404
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $23K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 56,912 shares bought, net +56,912 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| UBS Group AG | 0.00% | Add +377.5% | 33,812 | $25K |
| Two Sigma Securities, LLC | 0.00% | New | 15,348 | $12K |
| Geode Capital Management, LLC | 0.00% | New | 11,503 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,329 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 162 | $120 |
| Bank of America Corp. | 0.00% | Add +9.1% | 12 | $9 |
| Morgan Stanley | 0.00% | No change | 7 | $5 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $1 |
| BlackRock, Inc. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.